CGM After Discharge From Hospital
Continuous Glucose Monitoring for Post-discharge Diabetes Management
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Time periods mentioned: 28 days, 35 days
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits."
- "The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study compares two ways to check blood sugar after leaving the hospital in adults with type 2 diabetes or diabetes caused by steroid medicines who need insulin at home. One group will use a Libre 3 Plus continuous glucose monitor (CGM), a sensor that tracks blood sugar. The other group will use a CGM with hidden readings and fingerstick checks; both groups will wear sensors for 28 days and have remote diabetes care visits.
This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Age 18 or older.
- Treated in the hospital for type 2 diabetes or diabetes caused by steroid medicines, with plans to use insulin after leaving.
Who can't join
- Type 1 diabetes.
- Plans to go to a rehab center, skilled nursing facility, or hospice facility after leaving the hospital.
- A medical reason that prevents safe use of the sensor.
- Pregnant.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Adult 18 years or older. * Inpatient treatment for type 2 or steroid induced diabetes during hospitalization, with plan for insulin use after discharge. Exclusion Criteria: * Type 1 diabetes * Plan for discharge to rehabilitation/skilled nursing/hospice facility * Contra-indication to sensor placement * Pregnancy
Study sites (1)
NY
- Icahn School of Medicine at Mount Sinai · New York, NY 10035Grenye O'Malley, MD · Study contact · 212-241-7173 · grenye.o'malley@mssm.eduSophie Baum · Study contact · sophie.baum@mssm.eduGrenye O'Malley · Principal investigatorMore trials in New York